Skip to main content

Home/ Dr. Goodyear/ Group items tagged hemodialysis

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Low Serum Testosterone Increases Mortality Risk among Male Dialysis Patients - 0 views

jasn.asnjournals.org/...613.full

low serum testosterone mortality male patients hemodialysis CVD cardiovascular disease

shared by Nathan Goodyear on 26 Apr 12 - No Cached
  • Nathan Goodyear on 26 Apr 12
     
    low Testosterone associated with increased CVD in male hemodialysis patients
Nathan Goodyear

Testosterone and Hemoglobin in Hemodialysis Mal... [Artif Organs. 2013] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...24256140

testosterone hemoglobin dialysis

shared by Nathan Goodyear on 29 Nov 13 - No Cached
  • Nathan Goodyear on 29 Nov 13
     
    Testosterone levels associated with hemoglobin in men.  This association was statistically significant.  The association was less in women.  This study looked at hemodialysis patients only.
Nathan Goodyear

Effect of intravenous ascorbic ac... [Saudi J Kidney Dis Transpl. 2008] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...18974579

IV vitamin C IV vitamin C antioxidant antioxidants

shared by Nathan Goodyear on 25 Sep 13 - No Cached
  • Nathan Goodyear on 25 Sep 13
     
    IV vitamin C safe and improves response to EPO in those on hemodialysis.
Nathan Goodyear

Effect of intravenous ascorbic acid in hemod... [Am J Kidney Dis. 2006] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...16564942

IV vitamin C IV vitamin C antioxidant antioxidants anemia

shared by Nathan Goodyear on 25 Sep 13 - No Cached
  • Nathan Goodyear on 25 Sep 13
     
    High dose IV vitamin C shown to be well tolerated in those on hemodialysis.  Liver enzymes were followed throughout the course of the 6 month trial.  In fact, IV vitamin C was shown to improve the response of the EPO therapy.
Nathan Goodyear

Lipid peroxidation in hemodialysis patients: ef... [Clin Biochem. 2008] - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...18194672

IV vitamin C vitamin C lipid perioxidation antioxidants

shared by Nathan Goodyear on 05 Jun 13 - No Cached
  • Nathan Goodyear on 05 Jun 13
     
    IV vitamin C shown to reduce AGE and lipid hydroperoxide levels post IV vitamin C when compared prior and controls.
Nathan Goodyear

Kidney International - Abstract of article: Inflammation enhances cardiovascular risk a... - 0 views

www.nature.com/...4490624a.html

inflammation CRP cardiovascular disease risk

shared by Nathan Goodyear on 04 Feb 11 - No Cached
  • Nathan Goodyear on 04 Feb 11
     
    Inflammation (point 5 of 5 points of wellness) increases CRP, which increases cardiovascular risk
Nathan Goodyear

Access : Intravenous vitamin C can improve anemia in erythropoietin-hyporesponsive hemo... - 0 views

www.nature.com/...ncpneph0281.html

IV vitamin C vitamin C vitamin C IV intravenous vitamin C anemia

shared by Nathan Goodyear on 26 Aug 14 - No Cached
  • Nathan Goodyear on 26 Aug 14
     
    IV vitamin C improves anemia.  The only possible contribution of IV vitamin C and anemia is a G6PD deficiency.
Nathan Goodyear

Muscle Wasting in Hemodialysis Patients: New Therapeutic Strategies for Resolving an Ol... - 0 views

www.hindawi.com/...643954

low T low Testosterone Testosterone protein metabolism hormone hormones

shared by Nathan Goodyear on 06 Mar 15 - No Cached
  • Nathan Goodyear on 06 Mar 15
     
    Low Testosterone results in increased protein degradation.
Nathan Goodyear

Intravenous Ascorbate as a Tumor Cytotoxic Chemotherapeutic Agent - 0 views

www.seanet.com/...d_hypotheses_1995-v44-p207.htm

vitamin C cancer IV vitamin C ascorbic acid

shared by Nathan Goodyear on 05 Mar 18 - No Cached
  • There is a 10 — 100-fold greater content of catalase in normal cells than in tumor cells
  • induce hydrogen peroxide generation
  • Ascorbic acid and its salts (AA) are preferentially toxic to tumor cells in vitro (6 — 13) and in vivo
  • ...36 more annotations...
  • related to intracellular hydrogen peroxide generation
  • only be obtained by intravenous administration of AA
  • Preferentially kills neoplastic cells
  • Is virtually non-toxic at any dosage
  • Does not suppress the immune system, unlike most chemotherapy agents
  • Increases animal and human resistance to infectious agents by enhancing lymphocyte blastogenesis, enhancing cellular immunity, strengthening the extracellular matrix, and enhancing bactericidal activity of neutrophils and modulation of complement protein
  • Strengthens the structural integrity of the extracellular matrix which is responsible for stromal resistance to malignant invasiveness
  • 1969, researchers at the NCI reported AA was highly toxic to Ehrlich ascites cells in vitro
  • In 1977, Bram et al reported preferential AA toxicity for several malignant melanoma cell lines, including four human-derived lines
  • Noto et al reported that AA plus vitamin K3 had growth inhibiting action against three human tumor cell lines at non-toxic levels
  • Metabolites of AA have also shown antitumor activity in vitro
  • The AA begins to reduce cell proliferation in the tumor cell line at the lowest concentration, 1.76 mg/dl, and is completely cytotoxic to the cells at 7.04 mg/dl
  • the normal cells grew at an enhanced rate at the low dosages (1.76 and 3.52 mg/dl)
  • preferential toxicity of AA for tumor cells. >95% toxicity to human endometrial adenocarcinoma and pancreatic tumor cells (ATCC AN3-CA and MIA PaCa-2) occurred at 20 and 30 mg/dl, respectively.
  • No toxicity or inhibition was demonstrated in the normal, human skin fibroblasts (ATCC CCD 25SK) even at the highest concentration of 50 mg/dl.
  • the use of very high-dose intravenous AA for the treatment of cancer was proposed as early as 1971
  • Cameron and Pauling have published extensive suggestive evidence for prolonged life in terminal cancer patients orally supplemented (with and without initial intravenous AA therapy) with 10 g/day of AA
  • AA, plasma levels during infusion were not monitored,
  • the long-term, oral dosage used in those experiments (10 g/day), while substantial and capable of producing immunostimulatory and extracellular matrix modulation effects, was not high enough to achieve plasma concentrations that are generally cytotoxic to tumor cells in culture
  • This low cytotoxic level of AA is exceedingly rare
  • 5 — 40 mg/dl of AA is required in vitro to kill 100% of tumor cells within 3 days. The 100% kill levels of 30 mg/dl for the endometrial carcinoma cells and 40 mg/dl for the pancreatic carcinoma cells in Figure 2 are typical
  • normal range (95% range) of 0.39-1.13 mg/dl
  • 1 h after beginning his first 8-h infusion of 115 g AA (Merit Pharmaceuticals, Los Angeles, CA), the plasma AA was 3.7 mg/dl and at 5 h was 19 mg/dl. During his fourth 8-h infusion, 8 days later, the 1 h plasma level was 158 mg/dl and 5 h was 185 mg/dl
  • plasma levels of over 100 mg/dl have been maintained in 3 patients for more than 5 h using continuous intravenous infusion
  • In rare instances of patients with widely disseminated and rapidly proliferating tumors, intravenous AA administration (10 — 45 g/day) precipitated widespread tumor hemorrhage and necrosis, resulting in death
  • Although the outcomes were disastrous in these cases, they are similar to the description of tumor-necrosis-factor-induced hemorrhage and necrosis in mice (52) and seem to demonstrate the ability of AA to kill tumor cells in vivo.
  • toxic effects of AA on one normal cell line were observed at 58.36 mg/dl and the lack of side effects in patients maintaining >100 mg/dl plasma levels
  • Although it is very rare, tumor necrosis, hemorrhage, and subsequent death should be the highest priority concern for the safety of intravenous AA for cancer patients.
  • Klenner, who reported no ill effects of dosages as high as 150 g intravenously over a 24-h period
  • Cathcart (55) who describes no ill effects with doses of up to 200 g/d in patients with various pathological conditions
  • following circumstances: renal insufficiency, chronic hemodialysis patients, unusual forms of iron overload, and oxalate stone formers
  • Screening for red cell glucose-6-phosphate dehydrogenase deficiency, which can give rise to hemolysis of red blood cells under oxidative stress (57), should also be performed
  • any cancer therapy should be started at a low dosage to ensure that tumor hemorrhage does not occur.
  • patient is orally supplementing between infusions
  • a scorbutic rebound effect can be avoided with oral supplementation. Because of the possibility of a rebound effect, measurement of plasma levels during the periods between infusions should be performed to ensure that no such effect takes place
  • Every effort should be made to monitor plasma AA levels when a patient discontinues intravenous AA therapy.
  • Nathan Goodyear on 05 Mar 18
     
    Older study, 1995, but shows the long-standing evidence that IVC preferentially is cytotoxic to cancer cells.`
Nathan Goodyear

Ferritin Level Is Positively Associated with Chronic Kidney Disease in Korean Men, Base... - 0 views

www.ncbi.nlm.nih.gov/...PMC5129268

ferritin Iron kidney disease nutrition health

shared by Nathan Goodyear on 27 Sep 17 - No Cached
  • The overloading of body iron plays a role as an oxidative stressor
  • active radicals can affect lipids, proteins, and deoxyribonucleic acid (DNA), resulting in tissue injury and dysfunction
  • Excess iron causes oxidative stress and induces inflammation, leading to renal disease progression
  • ...4 more annotations...
  • Serum ferritin levels correlate with total body iron storage and systemic inflammation
  • The level of serum ferritin, an acute phase protein, is increased in an inflammatory environment
  • Previous studies have reported that elevated serum ferritin levels are associated with insulin resistance syndrome, hypertension, dyslipidemia, obesity, and metabolic syndrome as risk factors of CKD
  • elevated serum ferritin levels in hemodialysis patients predict higher mortality
  • Nathan Goodyear on 27 Sep 17
     
    great review and study: finds that elevated ferritin levels (> 200 ng/ml in men) was associated with increased chronic kidney disease in Korean study.
Nathan Goodyear

Vitamin C and functional iron deficiency anemia in hemodialysis - 0 views

www.ncbi.nlm.nih.gov/...PMC4715087

Iron anemia vitamin C Hepcidin

shared by Nathan Goodyear on 09 May 20 - No Cached
  • Nathan Goodyear on 09 May 20
     
    Proposed that IV vitamin C reduces Hepcidin induced anemia.
Nathan Goodyear

Effect of short-term intravenous ascorbic acid on reducing ferritin in hemodialysis pat... - 0 views

www.ncbi.nlm.nih.gov/...PMC3459518

ferritin vitamin C IV vitamin C

shared by Nathan Goodyear on 24 May 20 - No Cached
  • Nathan Goodyear on 24 May 20
     
    low dose IV vitamin C in patients with dialysis found to lower ferritin levels.
1 - 13 of 13
Showing 20▼ items per page